Metastatic Colorectal cancer (mCRC) research hub
6 indexed studies · 5 currently recruiting
- recruitingPhase II and Phase III (Integrated)
A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory colorectal cancer patients (TROPHIT1)
This study is looking at a new treatment called sacituzumab govitecan for bowel cancer that has spread and isn't responding to other treatments. It compares this new drug to standard treatments to see which works best at stopping the cancer from growing.
Germany - recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
This study looks at a new drug, magrolimab, combined with standard treatments for advanced bowel cancer that has spread and can't be operated on. It aims to see if this new combination is safe and helps people live longer without their cancer getting worse.
Germany · Spain · France - recruiting
Fruquintinib in Patients With Metastatic Colorectal Cancer
This study in Germany looks at how well a medicine called Fruquintinib works for people with bowel cancer that has spread. It focuses on patients who have already tried standard treatments. We want to see how patients respond, how long they live, their quality of life, and if the drug is safe.
Germany - active not recruitingPHASE3
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
This study is testing a new combination of two drugs, Regorafenib and Irinotecan, for people with advanced bowel cancer. It's comparing this new combination to Regorafenib on its own, to see if the combination works better when standard treatments are no longer effective.
France - recruitingPHASE1, PHASE2
A Clinical Study of Arfolitixorin in Patients With mCRC
This study is testing a new cancer medicine, arfolitixorin, for people with bowel cancer that has spread. It compares arfolitixorin to the usual treatment (leucovorin) to see if it's safer, works better, and to find the right dose alongside other standard medicines.
Germany - recruitingNA
DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit
This study is testing a new way to find a specific gene change (KRAS G12C) in people with advanced bowel cancer. This test helps see if a new medicine, sotorasib, might work for them. It's happening alongside a bigger study looking at how well sotorasib works.
United Kingdom